SCHEMBL4999845

SCHEMBL4999845

CCCN(CCOC)c1ccc(N/C=C2/C(=O)Nc3ccccc32)cc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.36
TDP1 Q9NUW8 2/20 0.35
RET P07949 1/20 0.35
ERBB2 P04626 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
TLK2 Q86UE8 1/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPT P10636 3/20 0.34
CSNK1D P48730 3/20 0.34
LMNA P02545 2/20 0.34
CSNK1A1 P48729 2/20 0.34
CSNK1E P49674 2/20 0.34
EGFR P00533 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TGM2 P21980 1/20 0.34
HTT P42858 1/20 0.34
IDO1 P14902 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GMNN O75496 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4999847 1.00 MDM2 (0.36) MDM2TDP1RETERBB2SMN1; SMN2
SCHEMBL4990581 0.92 ERBB2 (0.36) MDM2TDP1RETERBB2SMN1; SMN2
SCHEMBL4996382 0.89 MDM2 (0.38) MDM2TDP1RETSMN1; SMN2ALDH1A1
SCHEMBL4996379 0.89 MDM2 (0.38) MDM2TDP1RETSMN1; SMN2ALDH1A1
SCHEMBL4996972 0.84 NTRK1 (0.41) RETTLK2CSNK1DLMNACSNK1A1
SCHEMBL4996963 0.84 NTRK1 (0.41) RETTLK2CSNK1DLMNACSNK1A1
SCHEMBL4990805 0.83 NTRK1 (0.44) RETTLK2CSNK1DLMNACSNK1A1
SCHEMBL4990797 0.83 NTRK1 (0.44) RETTLK2CSNK1DLMNACSNK1A1
SCHEMBL4992099 0.82 MAPT (0.41) MDM2TDP1SMN1; SMN2ALDH1A1MAPT
SCHEMBL4992105 0.82 MAPT (0.41) MDM2TDP1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MDM2 282/4885TDP1 1661/4885RET 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.